PXD069058 is an
original dataset announced via ProteomeXchange.
Dataset Summary
| Title | Exploring red blood cells as an antigen delivery system to modulate the immune response towards FVIII in hemophilia A |
| Description | Background: The main complication in hemophilia A treatment is the development of inhibitory antibodies against factor (F)VIII. Immune tolerance induction, the gold standard for eradicating anti-FVIII antibodies, is efficient in only 60% to 80% of cases. This underscores the need for more efficient induction of tolerance in patients with hemophilia A with FVIII inhibitors. Objectives: In this study, we explored whether red blood cells (RBCs) can be utilized as antigen delivery system to modulate the immune response against FVIII. Methods: Two promiscuously HLA-DR–presented peptides derived from the A2 and C1 domains of FVIII were fused to the TAT cell-penetrating peptide and incubated with RBCs. Results: Biotinylated TAT-A2 and TAT-C1 peptides were found to interact with RBCs as shown by flow cytometry and imaging flow cytometry. Moreover, macrophages efficiently phagocytosed TAT-FVIII peptide–treated RBCs. Using mass spectrometry– based immunopeptidomics we established that TAT-FVIII peptides were presented on major histocompatibility complex class II of macrophages that phagocytosed TAT peptide–pulsed RBCs. Specifically, the TAT-A2 peptide exhibited efficient processing and presentation on HLA-DR molecules. Importantly, incubation of TAT-C1 peptide– treated RBCs-loaded macrophages with a FVIII-specific T-cell hybridoma led to a significant increase in IL-2 production, suggesting functional presentation of TAT-C1– derived peptides by macrophages. Conclusion: Our findings indicate that RBCs can serve as effective vehicle for the delivery of FVIII-derived peptides to antigen-presenting cells. The successful display of T-cell epitopes on antigen-presenting cell using ex vivo–loaded RBC may be potentially utilized to modulate pathogenic immune responses such as observed in a subset of patients with hemophilia A. |
| HostingRepository | PRIDE |
| AnnounceDate | 2025-10-02 |
| AnnouncementXML | Submission_2025-10-02_02:29:26.124.xml |
| DigitalObjectIdentifier | |
| ReviewLevel | Peer-reviewed dataset |
| DatasetOrigin | Original dataset |
| RepositorySupport | Unsupported dataset by repository |
| PrimarySubmitter | Arie Hoogendijk |
| SpeciesList | scientific name: Homo sapiens (Human); NCBI TaxID: 9606; |
| ModificationList | No PTMs are included in the dataset |
| Instrument | Orbitrap Fusion Lumos |
Dataset History
| Revision | Datetime | Status | ChangeLog Entry |
| 0 | 2025-10-01 16:36:52 | ID requested | |
| ⏵ 1 | 2025-10-02 02:29:27 | announced | |
Publication List
| 10.1016/j.jtha.2024.11.012; |
| Miranda M, Brandsma E, Robben L, Van Dender H, van Alphen FPJ, Fijnvandraat K, van den Biggelaar M, Lacroix-Desmazes S, van Bruggen R, Voorberg J, Exploring red blood cells as an antigen delivery system to modulate the immune response towards FVIII in hemophilia A. J Thromb Haemost, 23(3):836-848(2025) [pubmed] |
Keyword List
| submitter keyword: hemophilia A,erythrocytes, inhibitors, immunity, factor VIII |
Contact List
| A.J. Hoogendijk |
| contact affiliation | Sanquin Research, Amsterdam, NL |
| contact email | a.hoogendijk@sanquin.nl |
| lab head | |
| Arie Hoogendijk |
| contact affiliation | Sanquin Research, Amsterdam |
| contact email | a.hoogendijk@sanquin.nl |
| dataset submitter | |
Full Dataset Link List
Dataset FTP location
NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2025/10/PXD069058 |
| PRIDE project URI |
Repository Record List
[ + ]
[ - ]
- PRIDE
- PXD069058
- Label: PRIDE project
- Name: Exploring red blood cells as an antigen delivery system to modulate the immune response towards FVIII in hemophilia A